Publications by authors named "Shawn Gugliandolo"
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as important agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT2 inhibitors have been associated with improved cardiovascular outcomes, not only through their immediate hemodynamic effects-such as glycosuria and (at least temporary) increased natriuresis-but also due to their multifaceted impact on metabolism. Recently, studies have also focused on the effects of SGLT2 inhibitors on adipose tissue.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined the effects of the SGLT-2 inhibitor dapagliflozin on epicardial adipose tissue (EAT) and glucose metabolism in type 2 diabetes patients with stable coronary artery disease.
- - Dapagliflozin treatment resulted in a significant 19% reduction in EAT thickness and a 21.6% decrease in EAT glucose uptake compared to placebo after 4 weeks.
- - These findings suggest that SGLT-2 inhibitors may benefit cardiovascular health by targeting specific fat deposits related to inflammation and metabolism.
Objective: Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates for heart failure (HF). However, the mechanisms behind these benefits are not fully understood. This study was performed to investigate the effects of the SGLT-2i dapagliflozin on myocardial perfusion and glucose metabolism in patients with T2D and stable coronary artery disease (coronary stenosis ≥ 30% and < 80%), with or without previous percutaneous coronary intervention (> 6 months) but no HF.
View Article and Find Full Text PDF